Baudax Bio Announces Corporate Update
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A...
0.0106 | |
0.0103 | |
- | |
0.0111 | |
0.0103 | |
0.0103-1.4299 | |
950 K | |
43 593 K | |
1 269 K | |
-0.3 | |
1.583 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A...
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) th...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: